Founder's Letter
From my first psilocybin mushroom experience, I knew my life would be dedicated to engaging our fungal allies to help people and the planet. I am so honored to be chosen for shepherding this sacred wisdom, as one leader in a long lineage of experts. The mushrooms have taught me the importance of courage, kindness, strength and wisdom. But frankly, I could not begin to imagine the depth of meaning and purpose that mushrooms had in store for me. I feel blessed with the responsibility of creating a vessel that can carry this mission forward. That vessel is MycoMedica Life Sciences, formed as a Public Benefit Corporation. My team and I invite you to join us on this epic journey. We need to join together—and will succeed with the help of those who understand the intrinsic connection and wisdom the mushrooms have shown us. We have a future to co-create. We have a future to co-nurture. We have a duty to our ancestors and descendants, who are listening, watching and guiding us. Please help fuel and guide Starship MycoMedica Life Sciences.
Our Team
Driven by passion, our team brings years of practical experience and focus to help make MycoMedica's vision a reality.
Photo Credit: Trav Williams, Broken Banjo Photography
Paul Stamets
Founder & CEO
Paul Stamets, speaker, author, mycologist, medical researcher and entrepreneur, is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. His research is considered breakthrough by thought leaders for creating a paradigm shift for helping ecosystems worldwide. He has received numerous awards, including: Invention Ambassador (2014-2015) for the American Association for the Advancement of Science (AAAS), the National Mycologist Award (2014) from the North American Mycological Association (NAMA), and the Gordon & Tina Wasson Award (2015) from the Mycological Society of America (MSA). In 2020, Paul was inducted into the Explorer’s Club. He has been awarded myriad patents in the field of mycology. Paul is the founder and sole owner of Fungi Perfecti, LLC, the maker and marketer of the category-leading myco-supplement Host Defense line.
Pamela Kryskow
Co-Founder &Scientific and Medical Advisor
Pamela Kryskow, MD, is a clinical instructor at the University of British Columbia and adjunct professor at Vancouver Island University. Her research focuses on psilocybin, MDMA and ketamine. She is the medical lead in a psychedelic therapy program for health care providers and first responders.
Tad Buchanan
Co-Founder &Chief Financial Officer
Tad co-founded the investment firm of Buchanan Investments, Inc. in 1998. He previously served as Executive Director at UBS Securities (Hong Kong and NYC) and holds an MBA from Boston College. He has 25+ years of venture capital and private equity investment experience.
Dr. Sanjay Dubé
President &Chief Medical Officer
Former head of clinical development and scientific strategy at Avanir Pharmaceuticals (Otsuka Pharma). Lead for several late and early-stage drug candidates at Theravance and Eli Lilly. Distinguished Fellow of the APA and Adjunct Professor, Dept. of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. Received his medical degree (M.B; B.S) and M.D (honors) in Psychiatry at King George’s Medical University, India, and subsequently at Wayne State and University of Pittsburgh. Expertise in mood and anxiety disorders and treatment resistant depression (approval of SYMBYAX ®), schizophrenia, neurodegenerative disorders (Alzheimer’s disease, ALS, Parkinson’s, PBA), traumatic brain injury and other neuropsychiatric disorders.
Nick Moore
Chief Scientific Officer
Nick is an internationally recognized drug discovery and development specialist who has spent nearly 40 years working in the field. Previous roles include research appointments at Eli Lilly, Lundbeck Research USA, and Albany Molecular Research Inc. (AMRI) and scientific advisory roles at Brains On-Line (now part of Charles River Laboratories). Nick earned a doctorate in Neuropharmacology from the University of Birmingham, England. Career highlights include leading the preclinical team involved in the development of Lilly’s antipsychotic drug Zyprexa (olanzapine) and Lundbeck’s antidepressant Trintellix/Brintellix (vortioxetine). In 1999, he received the prestigious ‘Society for Medicines Research Award for Drug Discovery’ for his contributions to the discovery and development of Zyprexa.
Joanna Bolger
Vice President and Head of Operations (Development)
Joanna Bolger is the Vice President and Head of Operations (Development) at MycoMedica Life Sciences. Throughout her nearly 20-year career she has held positions of increasing responsibility in clinical operations and clinical program management. Prior to joining MycoMedica Life Sciences, Ms. Bolger was a Vice President of Clinical Operations at Cortexyme, where she provided oversight and management of the company’s global clinical program in Alzheimer’s Disease. She previously oversaw multiple adult and pediatric programs in oncology and rare metabolic disorders at Fate Therapeutics. Prior to this role, she was the Global Phase 3 Clinical Operations Leader at Cytori Therapeutics, overseeing medical device and biologic (adipose derived stem cell) combo therapy for the treatment of acute myocardial infarction. She has worked as a member of the clinical operations teams at Trius Therapeutics, Phenomix Corporation and Amylin Pharmaceuticals. Ms. Bolger holds a master’s in management and marketing degree and a mechanical engineering degree from the University of Technology in Warsaw (Politechnika Warszawska).
Investors
MycoMedica is funded by a group of mission and values aligned investors who believe in our vision.
News
06/30/22Nature
06/14/22CISION PR Newswire
06/01/22GlobalNewswire
05/27/22CNN
